ORPHA:36412
Hypocomplementemic urticarial vasculitis
Also known as: Anti-C1q vasculitis · Mac Duffie hypocomplementemic urticarial vasculitis · Mac Duffie syndrome · McDuffie hypocomplementemic urticarial vasculitis · McDuffie syndrome
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
952
90.5th percentile
Trials
0
Interventional, condition-specific
Researchers
1,206
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare immune complex-mediated small vessel vasculitis characterized by urticaria and hypocomplementemia (low C3, C4 and/or C1q), and usually associated with circulating anti-C1q autoantibodies. Arthritis, pulmonary disease, ocular inflammation are common systemic manifestations.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0018227
- UMLS:C0343206
Additional Mondo synonyms (1)
anti-C1q vasculitis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
952 matched papers (524 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 195 for broader category vasculitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
952
952 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
952 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
524 in the last 10 years · high confidence · 90.5th percentile (publications denominator)
Phrase hits: 952 · MeSH hits: 0
Who's working on it?
1,206
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Terrier B5 papers · 2022
Assistance Publique-Hôpitaux de Paris, Département de Médecine Interne, Centre de Référence National pour les maladies auto-immunes systémiques rares, Hôpital Cochin.
Papers in Europe PMC - 02Belot A4 papers · 2026
The International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France. alexandre.belot@chu-lyon.fr.
Papers in Europe PMC - 03Jachiet M4 papers · 2022
Department of Dermatology, Saint-Louis Hospital, Paris, France.
Papers in Europe PMC - 04Tusseau M4 papers · 2026
The International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
Papers in Europe PMC - 05Gonçalo M3 papers · 2025
Dermatology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
Papers in Europe PMC - 06Khan S3 papers · 2025
Department of Radiology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, United Kingdom.
Papers in Europe PMC - 07Moranne O3 papers · 2026
Service de Nephrologie-Dialyse-Apherese, Hôpital Universitaire Carémeau Nimes, IDESP Université de Montpellier, France.
Papers in Europe PMC - 08Romagnani P3 papers · 2024
Nephrology Unit, Anna Meyer Children Hospital and University of Florence, University of Florence, Florence, Italy.
Papers in Europe PMC - 09Zhu Y3 papers · 2026
The Affiliated Changsha Central Hospital, Center of Tuberculosis Diagnosis and Treatment, Hengyang Medical School, University of South China, Changsha, Hunan, People's Republic of China.
Papers in Europe PMC - 10Abdwani R2 papers · 2025
Child Health Department, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 195 trials are registered for vasculitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
195 interventional trials matched vasculitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: vasculitis
195
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07388277·RECRUITING·CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Conditions: Antineutrophil Cytoplasmic Antibody-associated Vasculitis·Matched via name phrase
- NCT06277427·RECRUITING·Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells
Conditions: Lupus Nephritis · ANCA Associated Vasculitis·Matched via name phrase
- NCT07448454·NOT YET RECRUITING·Role of Vessel Wall MRI in Differentiaition Between Intracranial Atherosclerotic Disease and Vasculitis as Causes of Ischemic Stroke
Conditions: Intracranial Atherosclerotic Disease (ICAD) and Vasculitis·Matched via name phrase
- NCT07268521·NOT YET RECRUITING·A Multicenter Phase 2 Single-arm Proof-of-concept Trial Assessing the Efficacy and Safety of Obinutuzumab in the Treatment of Non-infectious Active Cryoglobulinemia Vasculitis Refractory or Intolerant to Rituximab
Conditions: Cryoglobulinemic Vasculitis (CV)·Matched via name phrase
- NCT07315087·RECRUITING·CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases
Conditions: SLE - Systemic Lupus Erythematosus · SSc-Systemic Sclerosis · IIM- Idiopathic Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06986018·NOT YET RECRUITING·Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV
Conditions: Idiopathic Inflammatory Myopathies · ANCA-Associated Vasculitis·Matched via name phrase
- NCT06980597·RECRUITING·A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Idiopathic Inflammatory Myopathy (IIM) · Systemic Sclerosis (SSc) · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06821659·NOT YET RECRUITING·Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined with Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erthematosus · Systemic Sclerosis (SSc) · Inflammatory Myopathies · ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06868290·RECRUITING·Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA
Conditions: ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT06335888·RECRUITING·A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
Conditions: Giant Cell Arteritis·Matched via name phrase
- NCT07246096·RECRUITING·Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases
Conditions: Autoimmune Diseases · Systemic Lupus Erythematosus · Systemic Sclerosis · Primary Sjögren Syndrome·Matched via name phrase
- NCT06611696·RECRUITING·Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated Vasculitis
Conditions: ANCA Associated Vasculitis (AAV)·Matched via name phrase
- NCT07339540·RECRUITING·the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Conditions: Recurrent or Refractory Systemic Lupus Erythematosus · Recurrent or Refractory IgG4 Related Diseases · Recurrent or Refractory Systemic Sclerosis · Recurrent or Refractory Idiopathic Inflammatory Myopathy·Matched via name phrase
- NCT03290456·RECRUITING·Evaluate the Remission MAINtenance Using Extended Administration of Prednisone in Systemic Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis.
Conditions: Granulomatosis With Polyangitis·Matched via name phrase
- NCT07236801·RECRUITING·Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Systemic Sclerosis · Sjogren's Syndrome (SS) · Inflammatory Myopathy·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Hypocomplementemic urticarial vasculitis" OR "Anti-C1q vasculitis" OR "Mac Duffie hypocomplementemic urticarial vasculitis" OR "Mac Duffie syndrome" OR "McDuffie hypocomplementemic urticarial vasculitis" OR "McDuffie syndrome"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Hypocomplementemic urticarial vasculitis" OR "Anti-C1q vasculitis" OR "Mac Duffie hypocomplementemic urticarial vasculitis" OR "Mac Duffie syndrome" OR "McDuffie hypocomplementemic urticarial vasculitis" OR "McDuffie syndrome" OR "immune complex mediated vasculitis"
Recall-expansion terms: immune complex mediated vasculitis
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"vasculitis"
Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T23:54:35.555Z
